Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
- 15 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 100 (4), 1003-1012
- https://doi.org/10.1007/s00277-021-04451-w
Abstract
Chimeric antigen receptor (CAR) T cell therapy improves the remission rate of refractory/relapsed B-acute lymphoblastic leukemia (R/R B-ALL) patients, but the relapse rate remains high. Recent studies suggest patients who underwent post-chimeric antigen receptor T cell therapy hematopoietic stem cell transplantation (post- HSCT) would achieve durable remission and better survival, but this remains controversial. To this end, we conducted a meta-analysis to assess the role of post-HSCT in R/R B-ALL. The Cochrane Library, Embase, and PubMed were used to identify relevant studies; the latest search update was on July 05, 2020. We used the Cochran Q test and I-squared statistics to test for heterogeneity among the studies analyzed. The fixed model and random model were used to combine results when appropriate. We performed all statistical analyses with Stata 12, and P < 0.05 was considered statistically significant. We included 18 studies with 758 patients in the meta-analysis. Our results indicated that post-HSCT was associated with lower relapse rate (RR: 0.40, 95% CI: 0.32–0.50, P = 0.000), better overall survival (HR: 0.37, 95% CI: 0.19–0.71, P = 0.003), better leukemia-free survival (HR: 0.20, 95% CI: 0.10–0.40, P = 0.000). However, post-HSCT did not influence OS in Caucasians, and CAR-T cells with CD28 co-stimulation factor bridged to HSCT did not influence OS. Post-HSCT decreased the relapse rate and improved the long-term survival of R/R B-ALL patients. R/R B-ALL patients would benefit from post-HSCT after CAR-T cell therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81670179)
- major subject of science and technology of Anhui province (201903a07020030)
- Key Research and Development Plan of Anhui Province (201904a07020058)
- Foundation of Anhui Medical University (2019xkj134)
This publication has 46 references indexed in Scilit:
- Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation studyStatistics in Medicine, 2016
- Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationCancer, 2016
- Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Blood, 2016
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJCI Insight, 2016
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T CellsImmunity, 2016
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T CellsCancer Cell, 2015
- Engineered T cells for cancer therapyCancer Immunology, Immunotherapy, 2014
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countriesLeukemia, 2012